Repligen Corporation is a bioprocessing company that specializes in developing and manufacturing products that support the process of biologics, specifically in the production of therapeutics such as monoclonal antibodies and gene therapies
The company offers a range of innovative solutions, including critical components, systems, and services that enhance efficiency and reliability in biomanufacturing. By focusing on advanced technologies and customizable solutions, Repligen aims to improve the workflow of biopharmaceutical production, making it more cost-effective and scalable for its clients in the life sciences industry.
Biopharma manufacturing company Repligen Corporation (NASDAQRGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $697.5 million at the midpoint. Its non-GAAP profit of $0.44 per share was 7.9% above analysts’ consensus estimates.
Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has capped returns as the industry’s six-month gain of 1.2% has lagged the S&P 500’s 12.8% climb.
Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment.
Repligen reports Q2 sales of $154.1 million, closely matching the consensus estimate. Adjusted gross margin fell to 49.6% from 50.2%, with an EPS of $0.33. CEO Tony J. Hunt highlights strong Pharma demand and a pickup in CDMO activity.
